Treatment of pterygium by ligation and bevacizumab injection.
OBJECTIVE
To describe a technique for treating pterygium by combining a subpterygial injection of bevacizumab followed by pterygial ligation.


METHODS
Bevacizumab (1.25 mg/0.05 mL) was injected into the base of pterygia in 4 patients, and the pterygial necks were ligated.


RESULTS
The heads of the pterygia regressed and disappeared within 7 days after treatment. The bodies also partially regressed and well-defined vessels were not seen on the bodies; however, the concentration of microvessels was higher on the pterygial bodies than in the normal conjunctiva after 1 month. A recurrence was defined as fibrovascular growth of conjunctival tissue that extended beyond the limbus. No complications or recurrences were noted during the follow-up period.


CONCLUSIONS
Although only 4 cases were studied, the uniform finding demonstrated that combined subpterygial bevacizumab injection and pterygial ligation is a potential effective procedure for removing pterygium.
Department of Ophthalmology, Odawara Municipal Hospital, Odawara, Japan.
Houmei
H
Nakasato
Riyo
R
Uemoto
Nobuhisa
N
Mizuki
D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D000068258:Bevacizumab; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D015552:Injections, Intralesional; D008026:Ligation; D008297:Male; D011625:Pterygium / Q000188:drug therapy* / Q000601:surgery*; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab